Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
June 17, 2010
Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
The two areas, which have opportunities RXi's CEO called "tremendous" and "significant," have been well worn by rival drug companies making similar bets including Sirnaomics, TransDerm, and Quark Pharmaceuticals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.